Copyright © 2008 Min-Chul Cho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. E. Ravussin and C. Bouchard, “Human genomics and obesity: finding appropriate drug targets,” European Journal of Pharmacology, vol. 410, no. 2-3, pp. 131–145, 2000. View at Publisher · View at Google Scholar
2. T. B. Van Itallie, “Health implications of overweight and obesity in the United States,” Annals of Internal Medicine, vol. 103, no. 6, part 2, pp. 983–988, 1985.
3. M. Lafontan, “Fat cells: afferent and efferent messages define new approaches to treat obesity,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 119–146, 2005. View at Publisher · View at Google Scholar · View at PubMed
4. F. M. Gregoire, C. M. Smas, and H. S. Sul, “Understanding adipocyte differentiation,” Physiological Reviews, vol. 78, no. 3, pp. 783–809, 1998.
5. E. D. Rosen and B. M. Spiegelman, “Molecular regulation of adipogenesis,” Annual Review of Cell and Developmental Biology, vol. 16, pp. 145–171, 2000. View at Publisher · View at Google Scholar · View at PubMed
6. C.-S. Hwang, T. M. Loftus, S. Mandrup, and M. Daniel Lane, “Adipocyte differentiation and leptin expression,” Annual Review of Cell and Developmental Biology, vol. 13, pp. 231–259, 1997. View at Publisher · View at Google Scholar · View at PubMed
7. Q.-Q. Tang, J.-W. Zhang, and M. Daniel Lane, “Sequential gene promoter interactions by $\text{C/EBP}\beta$, $\text{C/EBP}\alpha$, and $\text{PPAR}\gamma$ during adipogenesis,” Biochemical and Biophysical Research Communications, vol. 318, no. 1, pp. 213–218, 2004. View at Publisher · View at Google Scholar · View at PubMed
8. P. A. Grimaldi, “Fatty acid regulation of gene expression,” Current Opinion in Clinical Nutrition & Metabolic Care, vol. 4, no. 5, pp. 433–437, 2001. View at Publisher · View at Google Scholar
9. B. M. Spieglelman and J. S. Flier, “Adipogenesis and obesity: rounding out the big picture,” Cell, vol. 87, no. 3, pp. 377–389, 1996. View at Publisher · View at Google Scholar
10. K. S. Cook, H. Y. Min, D. Johnson, et al., “Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve,” Science, vol. 237, no. 4813, pp. 402–405, 1987. View at Publisher · View at Google Scholar
11. M. Otero, R. Lago, F. Lago, et al., “Leptin, from fat to inflammation: old questions and new insights,” FEBS Letters, vol. 579, no. 2, pp. 295–301, 2005. View at Publisher · View at Google Scholar · View at PubMed
12. A. H. Berg, T. P. Combs, and P. E. Scherer, “ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism,” Trends Endocrinology and Metabolism, vol. 13, no. 2, pp. 84–89, 2002. View at Publisher · View at Google Scholar
13. M. Fasshauer, R. Paschke, and M. Stumvoll, “Adiponectin, obesity, and cardiovascular disease,” Biochimie, vol. 86, no. 11, pp. 779–784, 2004. View at Publisher · View at Google Scholar · View at PubMed
14. J. N. Fain, A. K. Madan, M. L. Hiler, P. Cheema, and S. W. Bahouth, “Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans,” Endocrinology, vol. 145, no. 5, pp. 2273–2282, 2004. View at Publisher · View at Google Scholar · View at PubMed
15. C. M. Steppan and M. A. Lazar, “Resistin and obesity-associated insulin resistance,” Trends in Endocrinology and Metabolism, vol. 13, no. 1, pp. 18–23, 2002. View at Publisher · View at Google Scholar
16. C. Hug and H. F. Lodish, “Visfatin: a new adipokine,” Science, vol. 307, no. 5708, pp. 366–367, 2005. View at Publisher · View at Google Scholar · View at PubMed
17. G. N. Chaldakov, I. S. Stankulov, M. Hristova, and P. I. Ghenev, “Adipobiology of disease: adipokines and adipokine-targeted pharmacology,” Current Pharmaceutical Design, vol. 9, no. 12, pp. 1023–1031, 2003. View at Publisher · View at Google Scholar
18. D. E. Moller and K. D. Kaufman, “Metabolic syndrome: a clinical and molecular perspective,” Annual Review of Medicine, vol. 56, pp. 45–62, 2005. View at Publisher · View at Google Scholar · View at PubMed
19. A. Tremblay and E. Doucet, “Obesity: a disease or a biological adaptation?,” Obesity Review, vol. 1, no. 1, pp. 27–35, 2000. View at Publisher · View at Google Scholar
20. H. Masuzaki, J. Paterson, H. Shinyama, et al., “A transgenic model of visceral obesity and the metabolic syndrome,” Science, vol. 294, no. 5549, pp. 2166–2170, 2001. View at Publisher · View at Google Scholar · View at PubMed
21. N. M. Morton, J. M. Paterson, H. Masuzaki, et al., “Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 $\beta$-hydroxysteroid dehydrogenase type 1-deficient mice,” Diabetes, vol. 53, no. 4, pp. 931–938, 2004. View at Publisher · View at Google Scholar
22. R. C. Andrews, O. Rooyackers, and B. R. Walker, “Effects of the 11 $\beta$-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes,” Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 1, pp. 285–291, 2003. View at Publisher · View at Google Scholar
23. G. Zhou, R. Myers, Y. Li, et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at PubMed
24. P. Cohen, M. Miyazaki, N. D. Socci, et al., “Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss,” Science, vol. 297, no. 5579, pp. 240–243, 2002. View at Publisher · View at Google Scholar · View at PubMed
25. M. Yuan, N. Konstantopoulos, J. Lee, et al., “Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk$\beta$,” Science, vol. 293, no. 5535, pp. 1673–1677, 2001. View at Publisher · View at Google Scholar · View at PubMed
26. M. Elchebly, P. Payette, E. Michaliszyn, et al., “Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene,” Science, vol. 283, no. 5407, pp. 1544–1548, 1999. View at Publisher · View at Google Scholar
27. L. Abu-Elheiga, M. M. Matzuk, K. A. Abo-Hashema, and S. J. Wakil, “Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2,” Science, vol. 291, no. 5513, pp. 2613–2616, 2001. View at Publisher · View at Google Scholar · View at PubMed
28. H. J. Harwood, Jr., S. F. Peteras, L. D. Shelly, et al., “Isozyme-nonselective $N$ -substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals,” Journal of Biological Chemistry, vol. 278, no. 39, pp. 37099–37111, 2003. View at Publisher · View at Google Scholar · View at PubMed
29. E. A. Lock, A. M. Mitchell, and C. R. Elcombe, “Biochemical mechanisms of induction of hepatic peroxisome proliferation,” Annual Review of Pharmacology and Toxicology, vol. 29, pp. 145–163, 1989. View at Publisher · View at Google Scholar · View at PubMed
30. V. Giguère, “Orphan nuclear receptor: from gene to function,” Endocrinology Review, vol. 20, no. 5, pp. 689–725, 1999. View at Publisher · View at Google Scholar
31. A. Werman, A. Hollenberg, G. Solanes, C. Bjørbaek, A. J. Vidal-Puig, and J. S. Flier, “Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$). Differential activity of PPAR$\gamma$1 and -2 isoforms and influence of insulin,” Journal of Biological Chemistry, vol. 272, no. 32, pp. 20230–20235, 1997. View at Publisher · View at Google Scholar
32. R. A. Graves, P. Tontonoz, K. A. Platt, S. R. Ross, and B. M. Spiegelman, “Identification of a fat cell enhancer: analysis of requirements for adipose tissue-specific gene expression,” Journal of Cellular Biochemistry, vol. 49, no. 3, pp. 219–224, 1992. View at Publisher · View at Google Scholar · View at PubMed
33. W. K. Sumanasekera, E. S. Tien, J. W. Davis, II, R. Turpey, G. H. Perdew, and J. P. Vanden Heuvel, “Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-$\alpha$ (PPAR$\alpha$) and PPAR$\beta$ activity,” Biochemistry, vol. 42, no. 36, pp. 10726–10735, 2003. View at Publisher · View at Google Scholar · View at PubMed
34. A. W. Zimmerman and J. H. Veerkamp, “New insights into the structure and function of fatty acid-binding proteins,” Cellular and Molecular Life Sciences, vol. 59, no. 7, pp. 1196–1116, 2002. View at Publisher · View at Google Scholar
35. N.-S. Tan, N. S. Shaw, N. Vinckenbosch, et al., “Selective cooperation between fatty acid binding proteins and proxisome proliferator-activated receptors in regulating transcription,” Molecular and Cellular Biology, vol. 22, no. 14, pp. 5114–5127, 2002. View at Publisher · View at Google Scholar
36. A. Adida and F. Spener, “Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor $\gamma$ agonists in cultured cell,” Biochimica et Biophysica Acta, vol. 1761, no. 2, pp. 172–181, 2006. View at Publisher · View at Google Scholar · View at PubMed
37. Y. Zhu, C. Qi, M. S. Rao, and J. K. Reddy, “Cloning and identification of mouse steroid receptor coactivator-1(mSRC-1), as a coactivator of peroxisome proliferators-activated receptor $\gamma$,” Gene Expression, vol. 6, no. 3, pp. 185–195, 1996.
38. J. J. Voegel, M. J. Heine, C. Zechel, P. Chambon, and H. Gronemeyer, “TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors,” The EMBO Journal, vol. 15, no. 14, pp. 3667–3675, 1996.
39. J. Torchia, D. W. Rose, J. Inostroza, et al., “The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function,” Nature, vol. 387, no. 6634, pp. 677–684, 1997. View at Publisher · View at Google Scholar · View at PubMed
40. B. P. Kota, T. H.-W. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 85–94, 2005. View at Publisher · View at Google Scholar · View at PubMed
41. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at PubMed
42. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal $\beta$-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp. 879–887, 1992. View at Publisher · View at Google Scholar
43. S. A. Kliewer, B. M. Forman, B. Blumberg, et al., “Differential expression and activation of a family of murine peroxisome proliferators-activated receptors,” Proceedings of the National Academy of Science of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994. View at Publisher · View at Google Scholar
44. O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptor (PPARs): tissue distribution of PPAR-$\alpha$, -$\beta$, and -$\gamma$ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar
45. P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPAR$\gamma$ 2: tissue-specific regulator of an adipocyte enhancer,” Genes & Development, vol. 8, no. 10, pp. 1224–1234, 1994. View at Publisher · View at Google Scholar
46. K. Yu, W. Bayona, C. B. Kallen, et al., “Differntial activation of peroxisome proliferator-activators by eicosanoids,” Journal of Biological Chemistry, vol. 270, no. 41, pp. 23975–23983, 1995. View at Publisher · View at Google Scholar
47. R. Hertz, I. Berman, D. Keppler, and J. Bar-Tana, “Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR),” European Journal of Biochemistry, vol. 235, no. 1-2, pp. 242–247, 1996. View at Publisher · View at Google Scholar
48. J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, “Peroxisome proliferator-activated receptors $\alpha$ and $\gamma$ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997. View at Publisher · View at Google Scholar
49. A. Schmidt, N. Endo, S. J. Rutledge, R. Vogel, D. Shinar, and G. A. Rodan, “Identification of a new member of the steroid hormone receptor superfamily that is activated by a proxisome proliferators and fatty acids,” Molecular Endocrinolgoy, vol. 6, no. 10, pp. 1634–1641, 1992. View at Publisher · View at Google Scholar
50. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acid, and eicosanoids are ligands for peroxisome proliferators-activated receptors $\alpha$ and $\delta$,” Proceedings of the National Academy of Science of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at Publisher · View at Google Scholar
51. B. Desvergne and W. Wahli, “Peroxisome proliferators-activated receptors: nuclear control of metabolism,” Endocrinology Review, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
52. J. C. Corton, S. P. Anderson, and A. Stauber, “Central role of peroxisome proliferators-activated receptors in the actions of peroxisome proliferators,” Annual Review of Pharmacology and Toxicology, vol. 40, pp. 491–518, 2000. View at Publisher · View at Google Scholar · View at PubMed
53. C. Diradourian, J. Girard, and J.-P. Pégorier, “Phosphorylation of PPARs: from molecular characterization to physiological relevance,” Biochimie, vol. 87, no. 1, pp. 33–38, 2005. View at Publisher · View at Google Scholar · View at PubMed
54. D. Shao, S. M. Rangwala, S. T. Bailey, S. L. Krakow, M. J. Reginato, and M. A. Lazar, “Interdomain communication regulating ligand binding by PPAR-$\gamma$,” Nature, vol. 396, no. 6709, pp. 377–380, 1998. View at Publisher · View at Google Scholar · View at PubMed
55. G. Lazennec, L. Canaple, D. Saugy, and W. Wahli, “Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators,” Molecular Endocrinology, vol. 14, no. 12, pp. 1962–1975, 2000. View at Publisher · View at Google Scholar
56. Z. E. Floyd and J. M. Stephens, “Interferon-$\gamma$-mediated activation and ubiquitin-proteasome-dependent degradation of PPAR$\gamma$ in adipocytes,” Journal of Biological Chemistry, vol. 277, no. 6, pp. 4062–4068, 2002. View at Publisher · View at Google Scholar · View at PubMed
57. C. Blanquart, R. Mansouri, J.-C. Fruchart, B. Staels, and C. Glineur, “Different ways to regulate the PPAR$\alpha$ stability,” Biochemical and Biophysical Research Communications, vol. 319, no. 2, pp. 663–670, 2004. View at Publisher · View at Google Scholar · View at PubMed
58. T. Ohshima, H. Koga, and K. Shimotahno, “Transcriptional activity of peroxisome proliferator-activated receptor $\gamma$ is modulated by SUMO-1 modification,” Journal of Biological Chemistry, vol. 279, no. 28, pp. 29551–29557, 2004. View at Publisher · View at Google Scholar · View at PubMed
59. G. Pascual, A. L. Fong, S. Ogawa, et al., “A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-$\gamma$,” Nature, vol. 437, no. 7059, pp. 759–763, 2005. View at Publisher · View at Google Scholar · View at PubMed
60. D. Yamashita, T. Yamaguchi, M. Shimizu, N. Nakata, F. Hirose, and T. Osumi, “The transactivating function of peroxisome proliferator-activated receptor $\gamma$ is negatively regulated by SUMO conjugation in the amino-terminal domain,” Genes to Cells, vol. 9, no. 11, pp. 1017–1029, 2004. View at Publisher · View at Google Scholar · View at PubMed
61. S. Yu, S. Rao, and J. K. Reddy, “Peroxisome proliferators-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis,” Current Molecular Medicine, vol. 3, no. 6, pp. 561–572, 2003. View at Publisher · View at Google Scholar
62. C. J. Chou, M. Haluzik, C. Gregory, et al., “WY14,643, a peroxisome proliferators-activated receptor $\alpha$ (PPAR$\alpha$) agonist, improves hepatic and muscle steatosis and reverses insulin resistanc in lipoatrophic A-ZIP/F-1 mice,” Journal of Biological Chemistry, vol. 277, no. 27, pp. 24484–24489, 2002. View at Publisher · View at Google Scholar · View at PubMed
63. N. Vu-Dac, S. Chopin-Delannoy, P. Gervois, et al., “The nuclear receptors peroxisome proliferator-activated receptor $\alpha$ and Rev-erb$\alpha$ mediate the species-specific regulation of apolipoprotein A-1 expression by fibrates,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25713–25720, 1998. View at Publisher · View at Google Scholar
64. B. L. Knight, D. D. Patel, S. M. Humphreys, D. Wiggins, and G. F. Gibbons, “Inhibition of cholesterol absorption associated with a PPAR$\alpha$-dependent increase in ABC binding cassette transporter A1 in mice,” Journal of Lipid Research, vol. 44, no. 11, pp. 2049–2058, 2003. View at Publisher · View at Google Scholar · View at PubMed
65. T. Nakamachi, T. Nomiyama, F. Gizard, et al., “PPAR$\alpha$ agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes,” Diabetes, vol. 56, no. 6, pp. 1662–1670, 2007. View at Publisher · View at Google Scholar · View at PubMed
66. G. Chinetti, F. G. Gbaguidi, S. Griglio, et al., “CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors,” Circulation, vol. 101, no. 20, pp. 2411–2417, 2000.
67. A. C. Li and W. Palinski, “Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis,” Annual Review of Pharmacology and Toxicology, vol. 46, pp. 1–39, 2006. View at Publisher · View at Google Scholar · View at PubMed
68. R. A. Daynes and D. C. Jones, “Emerging roles of PPARs in inflammation and immunity,” Nature Reviews Immunology, vol. 2, no. 10, pp. 748–759, 2002. View at Publisher · View at Google Scholar · View at PubMed
69. R. Pakala, P. Kuchulakanti, S.-W. Rha, E. Cheneau, R. Baffour, and R. Waksman, “Peroxisome proliferators-activated receptor $\gamma$: its role in metabolic syndrome,” Cardiovascular Radiation Medicine, vol. 5, no. 2, pp. 97–103, 2004. View at Publisher · View at Google Scholar · View at PubMed
70. S. M. Rangwala and M. A. Lazar, “Peroxisome proliferators-activated receptor $\gamma$ in diabetes and metabolism,” Trends in Pharmacological Sciences, vol. 25, no. 6, pp. 331–336, 2004. View at Publisher · View at Google Scholar · View at PubMed
71. G. J. Murphy and J. C. Holder, “PPAR-$\gamma$ agonists: therapeutic role in diabetes, inflammation and cancer,” Trends in Pharmacological Sciences, vol. 21, no. 12, pp. 469–474, 2000. View at Publisher · View at Google Scholar
72. K. Schoonjans and J. Auwerx, “Thiaolidinediones: an update,” The Lancet, vol. 355, no. 9208, pp. 1008–1010, 2000. View at Publisher · View at Google Scholar
73. S. Mudaliar and R. R. Henry, “New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers,” Annual Review of Medicine, vol. 52, pp. 239–257, 2001. View at Publisher · View at Google Scholar · View at PubMed
74. A. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, “The role of peroxisome proliferator-activated receptor-$\beta$/$\delta$ in epithelial cell growth and differentiation,” Cellular Signalling, vol. 18, no. 1, pp. 9–20, 2006. View at Publisher · View at Google Scholar · View at PubMed
75. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPAR$\delta$: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at PubMed
76. G. Krey, O. Braissant, F. L'Horset, et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay,” Molecular Endocrinology, vol. 11, no. 6, pp. 779–791, 1997. View at Publisher · View at Google Scholar
77. H. Eric Xu, M. H. Lambert, V. G. Montana, et al., “Molecular recognition of fatty acids by peroxisome proliferator-activated receptors,” Molecular Cell, vol. 3, no. 3, pp. 397–403, 1999. View at Publisher · View at Google Scholar
78. A. Chawla, C.-H. Lee, Y. Barak, et al., “PPAR$\delta$ is a very low-density lipoprotein sensor in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 1268–1273, 2003. View at Publisher · View at Google Scholar · View at PubMed
79. W. R. Oliver, Jr., J. L. Shenk, M. R. Snaith, et al., “A selective peroxisome proliferator-activated receptor $\delta$ agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001. View at Publisher · View at Google Scholar · View at PubMed
80. T. Tanaka, J. Yamamoto, S. Iwasaki, et al., “Activation of peroxisome proliferator-activated receptor $\delta$ induces fatty acid $\beta$-oxidation in skeletal muscle and attenuates metabolic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924–15929, 2003. View at Publisher · View at Google Scholar · View at PubMed
81. J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPAR$\gamma$ and PPAR$\delta$ negatively regulate specific subsets of lipopolysaccharide and IFN-$\gamma$ target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003. View at Publisher · View at Google Scholar · View at PubMed
82. S. S. Deeb, L. Fajas, M. Nemoto, et al., “A Pro12Ala substitution in PPAR$\gamma$2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at PubMed
83. B. G. Shearer and A. N. Billin, “The next generation of PPAR drugs: do we have the tools to find them?,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1082–1093, 2007. View at Publisher · View at Google Scholar · View at PubMed
84. R. Nakano, E. Kurosaki, S. Yoshida, et al., “Antagonism of peroxisome proliferator-activated receptor $\gamma$ prevents high-fat diet-induced obesity in vivo,” Biochemical Pharmacology, vol. 72, no. 1, pp. 42–52, 2006. View at Publisher · View at Google Scholar · View at PubMed
85. J. Rieusset, F. Touri, L. Michalik, et al., “A new selective peroxisome proliferator-activated receptor $\gamma$ antagonist with antiobesity and antidiabetic activity,” Molecular Endocrinology, vol. 16, no. 11, pp. 2628–2644, 2002. View at Publisher · View at Google Scholar
86. S. Seber, S. Ucak, O. Basat, and Y. Altuntas, “The effect of dual PPAR $\alpha$/$\gamma$ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 71, no. 1, pp. 52–58, 2006. View at Publisher · View at Google Scholar · View at PubMed
87. C. Fiévet, J.-C. Fruchart, and B. Staels, “PPAR$\alpha$ and PPAR$\gamma$ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome,” Current Opinion in Pharmacology, vol. 6, no. 6, pp. 606–614, 2006. View at Publisher · View at Google Scholar · View at PubMed
88. P. Balakumar, M. Rose, S. S. Ganti, P. Krishan, and M. Singh, “PPAR dual agonists: are they opening Pandora's Box?,” Pharmacological Research, vol. 56, no. 2, pp. 91–98, 2007. View at Publisher · View at Google Scholar · View at PubMed
89. I. C. Gonzalez, J. Lamar, F. Iradier, et al., “Design and synthesis of a novel class of dual PPAR$\gamma$/$\delta$ agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 4, pp. 1052–1055, 2007. View at Publisher · View at Google Scholar · View at PubMed
90. Y. Xu, G. J. Etgen, C. L. Broderick, et al., “Design and synthesis of dual peroxisome proliferator-activated receptors $\gamma$ and $\delta$ agonists as novel euglycemic agents with a reduced weight gain profile,” Journal of Medicinal Chemistry, vol. 49, no. 19, pp. 5649–5652, 2006. View at Publisher · View at Google Scholar · View at PubMed
91. J. M. Wallace, M. Schwarz, P. Coward, et al., “Effects of peroxisome proliferator-activated receptor $\alpha$/$\delta$ agonists on HDL-cholesterol in vervet monkeys,” Journal of Lipid Research, vol. 46, no. 5, pp. 1009–1016, 2005. View at Publisher · View at Google Scholar · View at PubMed
92. L. Shen, Y. Zhang, A. Wang, et al., “Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors $\alpha$ and $\delta$,” Journal of Medicinal Chemistry, vol. 50, no. 16, pp. 3954–3963, 2007. View at Publisher · View at Google Scholar · View at PubMed
93. F. Zhang, B. E. Lavan, and F. M. Gregoire, “Selective modulators of PPAR-$\gamma$ activity: molecular aspects related to obesity and side-effects,” PPAR Research, vol. 2007, Article ID 32696, 7 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
94. T. Allen, F. Zhang, S. A. Moodie, et al., “Halofenate is a selective peroxisome proliferator-activated receptor $\gamma$ modulator with antidiabetic activity,” Diabetes, vol. 55, no. 9, pp. 2523–2533, 2006. View at Publisher · View at Google Scholar · View at PubMed
95. E. Burgermeister, A. Schnoebelen, A. Flament, et al., “A novel partial agonist of peroxisome proliferator-activated receptor-$\gamma$ (PPAR$\gamma$) recruits PPAR$\gamma$-coactivator-1$\alpha$, prevents triglyceride accumulation, and potentiates insulin signaling in vitro,” Molecular Endocrinology, vol. 20, no. 4, pp. 809–830, 2006. View at Publisher · View at Google Scholar · View at PubMed
96. A. Tenenbaum, M. Motro, and E. Z. Fisman, “Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons,” Cardiovascular Diabetology, vol. 4, article 14, 2005. View at Publisher · View at Google Scholar · View at PubMed
97. U. Ramachandran, R. Kumar, and A. Mittal, “Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome,” Mini Reviews in Medicinal Chemistry, vol. 6, no. 5, pp. 563–573, 2006. View at Publisher · View at Google Scholar
98. Q. Chen, J. Chen, T. Sun, J. Shen, X. Shen, and H. Jiang, “A yeast two-hybrid technology-based system for the discovery of PPAR$\gamma$ agonist and antagonist,” Analytical Biochemistry, vol. 335, no. 2, pp. 253–259, 2004. View at Publisher · View at Google Scholar · View at PubMed
99. R. T. Nolte, G. B. Wisely, S. Westin, et al., “Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-$\gamma$,” Nature, vol. 395, no. 6698, pp. 137–143, 1998. View at Publisher · View at Google Scholar · View at PubMed
100. S. Chen, B. A. Johnson, Y. Li, et al., “Both coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$) function,” Journal of Biological Chemistry, vol. 275, no. 6, pp. 3733–3736, 2000. View at Publisher · View at Google Scholar
101. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-${\Delta }^{12,14}$-prostaglandin ${\text{J}}_2$ is a ligand for the adipocyte determination factor PPAR$\gamma$,” Cell, vol. 83, no. 5, pp. 803–812, 1995. View at Publisher · View at Google Scholar
102. P. W. Young, D. R. Buckle, B. C. C. Cantello, et al., “Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor $\gamma$,” Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 2, pp. 751–759, 1998.
103. J. S. Nichols, D. J. Parks, T. G. Consler, and S. G. Blanchard, “Development of a scintillation proximity assay for peroxisome proliferator-activated receptor $\gamma$ ligand binding domain,” Analytical Biochemistry, vol. 257, no. 2, pp. 112–119, 1998. View at Publisher · View at Google Scholar · View at PubMed
104. A. Elbrecht, Y. Chen, A. Adams, et al., “L-764406 is a partial agonist of human peroxisome proliferator-activated receptor $\gamma$. The role of ${\text{Cys}}^{313}$ in ligand binding,” Journal of Biological Chemistry, vol. 274, no. 12, pp. 7913–7922, 1999. View at Publisher · View at Google Scholar
105. G. Zhou, R. Cummings, Y. Li, et al., “Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer,” Molecular Endocrinology, vol. 12, no. 10, pp. 1594–1604, 1998. View at Publisher · View at Google Scholar
106. G. Zhou, R. Cummings, J. Hermes, and D. E. Moller, “Use of homogeneous time-resolved fluorescence energy transfer in the measurement of nuclear receptor activation,” Methods, vol. 25, no. 1, pp. 54–61, 2001. View at Publisher · View at Google Scholar · View at PubMed
107. M.-C. Cho, H.-S. Lee, J. H. Kim, et al., “A simple ELISA for screening ligands of peroxisome proliferator-activated receptor $\gamma$,” Journal of Biochemistry and Molecular Biology, vol. 36, no. 2, pp. 207–213, 2003.
108. H.-S. Lee, M.-C. Cho, T.-W. Baek, et al., “Epitope analysis of PPAR$\gamma$ monoclonal antibody P$\gamma$48.34A and its application for screening PPAR$\gamma$ ligands,” Journal of Immunological Methods, vol. 296, no. 1-2, pp. 125–134, 2005. View at Publisher · View at Google Scholar · View at PubMed
109. M.-C. Cho, H.-E. Yoon, J.-W. Kang, et al., “A simple method to screen ligands of peroxisome proliferator-activated receptor $\delta$,” European Journal of Pharmaceutical Sciences, vol. 29, no. 5, pp. 355–360, 2006. View at Publisher · View at Google Scholar · View at PubMed
110. M. A. Cooper, “Optical biosensors in drug discovery,” Nature Reviews Drug Discovery, vol. 1, no. 7, pp. 515–528, 2002. View at Publisher · View at Google Scholar
111. B. Cheskis and L. P. Freedman, “Modulation of nuclear receptor interactions by ligands: kinetic analysis using surface plasmon resonance,” Biochemistry, vol. 35, no. 10, pp. 3309–3318, 1996. View at Publisher · View at Google Scholar · View at PubMed
112. C. Yu, L. Chen, H. Luo, et al., “Binding analyses between human PPAR$\gamma$-LBD and ligands: surface plasmon resonance biosensor assay correlating with circular dichroic spectroscopy determination and molecular docking,” European Journal of Biochemistry, vol. 271, no. 2, pp. 386–397, 2004. View at Publisher · View at Google Scholar
113. L. Yue, F. Ye, C. Gui, et al., “Ligand-binding regulation of LXR/RXR and LXR/PPAR heterodimerizations: SPR technology-based kinetic analysis correlated with molecular dynamics simulation,” Protein Science, vol. 14, no. 3, pp. 812–822, 2005. View at Publisher · View at Google Scholar · View at PubMed
114. T. Fujino, Y. Sato, M. Une, et al., “In vitro farnesoid X receptor ligand sensor assay using surface plasmon resonance and based on ligand-induced coactivator association,” Journal of Steroid Biochemistry and Molecular Biology, vol. 87, no. 4-5, pp. 247–252, 2003. View at Publisher · View at Google Scholar
115. T. Kanayasu-Toyoda, T. Fujino, T. Oshizawa, et al., “HX531, a retinoid X receptor antagonist, inhibited the 9-cis retinoic acid-induced binding with steroid receptor coactivator-1 as detected by surface plasmon resonance,” Journal of Steroid Biochemistry and Molecular Biology, vol. 94, no. 4, pp. 303–309, 2005. View at Publisher · View at Google Scholar · View at PubMed
116. J. K. Reddy, D. E. Moody, D. L. Azarnoff, and R. M. Tomarelli, “Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse,” Archives Internationales de Pharmacodynamie et de Therapie, vol. 225, no. 1, pp. 51–57, 1977.
117. T. Sohda, K. Mizuno, H. Tawada, Y. Sugiyama, T. Fujita, and Y. Kawamatsu, “Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl]thiazolidine-2,4-dione (AL-321) and related compounds,” Chemical & Pharmaceutical Bulletin, vol. 30, no. 10, pp. 3563–3573, 1982.
118. T. Fujita, Y. Sugiyama, S. Taketomi, et al., “Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent,” Diabetes, vol. 32, no. 9, pp. 804–810, 1983. View at Publisher · View at Google Scholar
119. S. E. Wiley, A. N. Murphy, S. A. Ross, P. van der Geer, and J. E. Dixon, “MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 13, pp. 5318–5323, 2007. View at Publisher · View at Google Scholar · View at PubMed